R&G PharmaStudies Co. Ltd. A Total Liabilities
R&G PharmaStudies Co. Ltd. A total liabilities. Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has total liabilities worth CN¥397.56 Million CNY (≈ $58.18 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 301333 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of R&G PharmaStudies Co. Ltd. A (2019–2025)
Total liabilities of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. This chart illustrates how R&G PharmaStudies Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.
R&G PharmaStudies Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥285.89 Million |
|
Yunnan Nantian Electronics Information Co Ltd
SHE:000948
|
China | CN¥5.53 Billion |
|
ProFrac Holding Corp.
NASDAQ:ACDC
|
USA | $1.79 Billion |
|
Jiangyin Electrical Alloy Co Ltd
SHE:300697
|
China | CN¥1.34 Billion |
|
Priortech
TA:PRTC
|
Israel | ILA123.21 Million |
|
USIMINAS PFD ADR/10000
F:U1S0
|
Germany | €11.46 Billion |
|
Multi Bintang Indonesia Tbk
JK:MLBI
|
Indonesia | Rp2.01 Trillion |
|
Hangzhou Advance Gearbox Group Co Ltd
SHG:601177
|
China | CN¥2.46 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down R&G PharmaStudies Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 301333 current and non-current assets.
Liquidity & Leverage Metrics
R&G PharmaStudies Co. Ltd. A Total Liabilities Ratios Explained
R&G PharmaStudies Co. Ltd. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how R&G PharmaStudies Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for R&G PharmaStudies Co. Ltd. A (2019–2025)
The table below shows the annual total liabilities of R&G PharmaStudies Co. Ltd. A from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥423.89 Million ≈ $62.03 Million |
-15.24% |
| 2024-12-31 | CN¥500.09 Million ≈ $73.18 Million |
+56.69% |
| 2023-12-31 | CN¥319.17 Million ≈ $46.70 Million |
+10.31% |
| 2022-12-31 | CN¥289.35 Million ≈ $42.34 Million |
+20.73% |
| 2021-12-31 | CN¥239.66 Million ≈ $35.07 Million |
+20.20% |
| 2020-12-31 | CN¥199.38 Million ≈ $29.17 Million |
+1.15% |
| 2019-12-31 | CN¥197.12 Million ≈ $28.84 Million |
-- |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more